Stockscreener 앱 받기
7.19
3.45%
0.24
시간 외 거래:
7.19
전일 마감가:
$6.95
열려 있는:
$7.09
하루 거래량:
1.45M
Relative Volume:
1.12
시가총액:
$646.69M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.6872
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
+12.70%
1개월 성능:
+2.86%
6개월 성능:
-47.71%
1년 성능:
-44.18%
1일 변동 폭
$7.02
$7.33
1주일 범위
$6.40
$7.33
52주 변동 폭
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
7.19 | 646.69M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Squarepoint Ops LLC Acquires New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - Insider Monkey
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
Nuveen Asset Management LLC Lowers Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Bought by Millennium Management LLC - Defense World
ProShare Advisors LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,894 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Cetera Investment Advisers Has $400,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
36,685 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by BNP Paribas Financial Markets - Defense World
D. E. Shaw & Co. Inc. Increases Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth - Yahoo Finance
Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day one Biopharmaceuticals officer sells $24,574 in stock By Investing.com - Investing.com Nigeria
Day one Biopharmaceuticals officer sells $24,574 in stock - Investing.com
Day One Biopharmaceuticals Executives Sell Shares to Cover Tax Liabilities - TradingView
Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN
Day One Biopharmaceuticals Insider Lowered Holding By 20% During Last Year - simplywall.st
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stake Decreased by Voya Investment Management LLC - Defense World
Transcript : Day One Biopharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? - MSN
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
Trend Tracker for (DAWN) - news.stocktradersdaily.com
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down – Here’s What Happened - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World
Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World
Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World
Day One Biopharma’s Earnings Call Highlights Growth - TipRanks
Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus
Needham Adjusts Price Target for DAWN to $27, Maintains Buy Rati - GuruFocus
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey
MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada
Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Reports First Quarter 2025 Financial Results and Corporate Progress - GlobeNewswire
Earnings call transcript: Day One Biopharmaceuticals beats Q1 2025 EPS forecast - Investing.com
Day One Biopharmaceuticals Q1 2025 slides: OJEMDA revenue grows 11% amid market challenges - Investing.com Canada
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Day One Biopharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Pr - GuruFocus
Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday - Defense World
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.51%
자본화:
|
볼륨(24시간):